Analystreport

Novelion Therapeutics Inc (NASDAQ: NVLN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock.

NOVELION THERAPEUTICS INC COMMON SHARES  (NVLN) 
Last novelion therapeutics inc common shares earnings: 5/7 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.novelion.com